In addition to being significantly lower compared with age- and gender-matched healthy controls, APOA-I levels also demonstrate distinct variations among the AD subjects, with lower concentrations directly correlating with the severity of cognitive impairment (as evidenced by a strong association between APOA-I levels and Mini-Mental State Examination) [88]. This evidence concerns the gene APOA1 and Cognitive impairment.